ClinicalTrials.gov
 Home    Search    Study Topics    Glossary  
 

  Full Text View  
  Tabular View  
  Contacts and Locations  
  Related Studies  
Effects of Ligands on Human Hair Follicles Grafted Onto SCID Mice

This study has been completed.

Sponsored by: Hordinsky, Maria K., MD
Information provided by: University of Minnesota
ClinicalTrials.gov Identifier: NCT00177099
  Purpose

The purpose of this study is to determine if immunophilin ligands may have the potential to reverse hair loss.


Condition Intervention Phase
Alopecia
Drug: FK506, GP11046, GP11511
Phase I

MedlinePlus related topics:   Hair Diseases and Hair Loss   

ChemIDplus related topics:   Tacrolimus    Tacrolimus anhydrous   

U.S. FDA Resources

Study Type:   Interventional
Study Design:   Treatment, Non-Randomized, Open Label, Placebo Control, Factorial Assignment, Efficacy Study
Official Title:   Neurotrophic Effects of Immunophilin Ligands on Human Hair Follicles Grafted Onto Service Combined Immunodeficient (SCID) Mice

Further study details as provided by University of Minnesota:

Primary Outcome Measures:
  • The average number of terminal hairs per graft will be compared between the control and the treated group.

Secondary Outcome Measures:
  • The number of follicles in anagen, catagen and telogen per graft will be averaged for each group. The results will be compared between the control and the treated groups.

Estimated Enrollment:   35
Study Start Date:   July 2003
Estimated Study Completion Date:   September 2004

Detailed Description:

Preliminary experiments in C57BL/6J mice showed that immunophilin ligand FK506 and its non-immunosuppressive analogs, GP11046 and GP11511 were capable of promoting telogen to anagen transition. Since GP11046 and GP11511 possess the neurotrophic properties of FK506 without its immunosuppressant capability, the neural action of these immunophilin ligands may play an important role in the hair cycle. This finding has significant clinical implications in that immunophilin ligands may have the potential to reverse alopecia. To further investigate this possibility we propose to explore the response of transplanted miniaturized scalp hair follicles to topically applied immunophilin ligands.

  Eligibility
Ages Eligible for Study:   18 Years to 65 Years
Genders Eligible for Study:   Male
Accepts Healthy Volunteers:   Yes

Criteria

Inclusion Criteria:

  • Healthy men ages 18-65 with Hamilton type IV or V alopecia

Exclusion Criteria:

  • Individuals who do not meet the inclusion criteria.
  Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00177099

Locations
United States, Minnesota
University of Minnesota    
      Minneapolis, Minnesota, United States, 55455

Sponsors and Collaborators
Hordinsky, Maria K., MD

Investigators
Principal Investigator:     Marna Ericson, Ph D     University of Minnesota    
Principal Investigator:     Maria Hordinsky, MD     University of Minnesota    
  More Information

Study ID Numbers:   0306M49486
First Received:   September 13, 2005
Last Updated:   November 8, 2006
ClinicalTrials.gov Identifier:   NCT00177099
Health Authority:   United States: Institutional Review Board

Study placed in the following topic categories:
Pathological Conditions, Anatomical
Skin Diseases
Alopecia
Tacrolimus
Immunologic Deficiency Syndromes

Additional relevant MeSH terms:
Hair Diseases
Hypotrichosis

ClinicalTrials.gov processed this record on September 05, 2008




Links to all studies - primarily for crawlers